HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target lowered by HC Wainwright from $12.00 to $11.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also weighed in on YMAB. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Truist Financial cut their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Oppenheimer cut their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Finally, Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.60.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $4.17 on Monday. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11. The stock has a market cap of $188.83 million, a price-to-earnings ratio of -7.72 and a beta of 0.53. The business has a fifty day moving average of $4.45 and a 200-day moving average of $6.93.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10. The business had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. On average, equities research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group lifted its stake in Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock worth $26,000 after acquiring an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Y-mAbs Therapeutics in the 4th quarter worth about $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Y-mAbs Therapeutics in the 1st quarter worth about $49,000. Corton Capital Inc. purchased a new stake in Y-mAbs Therapeutics in the 1st quarter worth about $55,000. Finally, EntryPoint Capital LLC purchased a new stake in Y-mAbs Therapeutics in the 1st quarter worth about $56,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.